Dexmedetomidine vs placebo in ERCP sedatio

• Conditions: ERCP(Endoscopic retrograde cholangiopancreatography); MedDRA version: 12.1Level: LLTClassification code 10049192Term: Pancreatic fistula; MedDRA version: 12.1Level: LLTClassification code 10052108Term: Pancreatic duct stone; MedDRA version: 12.1Level: HLTClassification code 10033634Term: Pancreatic therapeutic procedures; MedDRA version: 12.1Level: LLTClassification code 10033615Term: Pancreatic cyst; MedDRA version: 12.1Level: LLTClassification code 10033616Term: Pancreatic disorder; MedDRA version: 12.1Level: LLTClassification code 10033635Term: Pancreatic pseudocyst; MedDRA version: 12.1Level: LLTClassification code 10052377Term: Pancreatic sphincterotomy; MedDRA version: 12.1Level: LLTClassification code 10015115Term: ERCP

• Registration Number: EUCTR2009-014862-25-FI
• Lead Sponsor: Helsinki University Central Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-12-28
• Last Update Posted: 24 November 2014

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

-elective ERCP;
-alcohol dependence
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-inability to cooperate;
-allergy to propofol or dexmedetomidine ;
-ASA class greater then 3

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified